Shoulder Innovations (SI) announced that in addition to its already robust portfolio of issued intellectual property, SI received a first notice of allowance from the USPTO for the InSet Reverse System.
SI has developed and commercialized various components for the integrated InSet system, which includes the InSet Glenoid, Humeral Short Stem, Reverse and Stemless components. A platform of several technologies, the InSet Reverse System includes this first notice of allowance that has issued from USPTO for an enhanced solution to optimize the potential for fixation and for intraoperative glenosphere insertion and assembly.
The company received FDA clearance to market their InSet Reverse Shoulder Arthroplasty System in 2021.
Rob Ball, CEO of Shoulder Innovations, said, “SI released its InSet Reverse system almost two years ago, and the company has enjoyed a positive response from the marketplace. There is a significant amount of technology packaged into this system and this patent represents an important component of that technology platform. The uniqueness and value of the combination of a central bone fixation screw stabilized by a compression nut, which is in turn supported by a glenoid locking bolt, is validated by this Notice of Allowance by the USPTO.”
Shoulder Innovations (SI) announced that in addition to its already robust portfolio of issued intellectual property, SI received a first notice of allowance from the USPTO for the InSet Reverse System.
SI has developed and commercialized various components for the integrated InSet system, which includes the InSet Glenoid, Humeral Short Stem,...
Shoulder Innovations (SI) announced that in addition to its already robust portfolio of issued intellectual property, SI received a first notice of allowance from the USPTO for the InSet Reverse System.
SI has developed and commercialized various components for the integrated InSet system, which includes the InSet Glenoid, Humeral Short Stem, Reverse and Stemless components. A platform of several technologies, the InSet Reverse System includes this first notice of allowance that has issued from USPTO for an enhanced solution to optimize the potential for fixation and for intraoperative glenosphere insertion and assembly.
The company received FDA clearance to market their InSet Reverse Shoulder Arthroplasty System in 2021.
Rob Ball, CEO of Shoulder Innovations, said, “SI released its InSet Reverse system almost two years ago, and the company has enjoyed a positive response from the marketplace. There is a significant amount of technology packaged into this system and this patent represents an important component of that technology platform. The uniqueness and value of the combination of a central bone fixation screw stabilized by a compression nut, which is in turn supported by a glenoid locking bolt, is validated by this Notice of Allowance by the USPTO.”
Copy to clipboard 
